

**Arecor Therapeutics plc**  
("Arecor" or the "Company")

**ARECOR SELLS RIGHTS TO NON-UGLUO® PRODUCTS FROM TETRIS PHARMA PORTFOLIO TO ASPIRE PHARMA**

**Cambridge, UK, 8th May 2025** Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces the sale of rights to certain non-UGluo® products from the portfolio of its Tetris Pharma subsidiary to Aspire Pharma Limited ("Aspire").

Under the terms of the agreement, Arecor will receive a cash payment of £0.5 million from Aspire in return for both the UK distribution rights to the products and the transfer of existing inventory. There is no separate financial information available in relation to the rights of the non-UGluo® products being sold. The Board intends to use the proceeds of the Transaction for working capital purposes.

This agreement is part of the orderly cessation of Tetris Pharma operations, as announced in January 2025, and the Company's strategic focus on areas which best leverage its platform and resources to deliver transformational value opportunities.

**For more information, please contact:**

**Arecor Therapeutics plc**

Dr Sarah Howell, Chief Executive Officer

[www.arecor.com](http://www.arecor.com)

Tel: +44 (0) 1223 426060

Email: [info@arecor.com](mailto:info@arecor.com)

David Ellam, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: [info@arecor.com](mailto:info@arecor.com)

**Singer Capital Markets Advisory LLP (NOMAD and Broker)**

Phil Davies, Sam Butcher

Tel: +44 (0) 20 7496 3000

**ICR Healthcare**

Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: [arecor@icrhealthcare.com](mailto:arecor@icrhealthcare.com)

**Notes to Editors**

**About Arecor**

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, [www.arecor.com](http://www.arecor.com)

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCUBSKRVSUVRAR